Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia-Reference-Cited by-同舟云学术

Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia

Published:2024-06-01 Issue:6 Volume:10 Page:821
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Phely Laurent¹,Hensen Luca¹,Faul Christoph¹,Ruff Christer Alexander²,Schneider Dina³,Bethge Wolfgang Andreas¹,Lengerke Claudia¹

Affiliation:

1. Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tuebingen, Germany

2. Department of Diagnostic and Interventional Neuroradiology, University Hospital Tubingen, Tubingen, Germany

3. Miltenyi Biotec, Gaithersburg, Maryland

Abstract

This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells.

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2817659/jamaoncology_phely_2024_ld_240002_1718739255.37513.pdf

Reference6 articles.

1. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.;Shah;Lancet,2021

2. Tumor antigen escape from CAR T-cell therapy.;Majzner;Cancer Discov,2018

3. Phase 1 study of CD19/CD22 bispecific chimeric antigen receptor (CAR) therapy in children and young adults with B cell acute lymphoblastic leukemia (ALL).;Schultz;Blood,2018

4. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.;Spiegel;Nat Med,2021

5. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome.;Pecher;JAMA,2023